Published in J Med Chem on April 19, 2007
Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model. Cancer Prev Res (Phila) (2011) 1.19
Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras. Biochem Pharmacol (2012) 1.19
NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide (2008) 1.16
Nitric oxide and cancer therapy: the emperor has NO clothes. Curr Pharm Des (2010) 1.05
Prochelator BHAPI protects cells against paraquat-induced damage by ROS-triggered iron chelation. Metallomics (2012) 1.04
NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals. ACS Med Chem Lett (2012) 1.03
NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols. J Transl Med (2008) 0.85
Nitrates and NO-NSAIDs in cancer chemoprevention and therapy: in vitro evidence querying the NO donor functionality. Nitric Oxide (2008) 0.84
Synthesis and chemical and biological comparison of nitroxyl- and nitric oxide-releasing diazeniumdiolate-based aspirin derivatives. J Med Chem (2013) 0.83
Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review. Int J Mol Sci (2012) 0.82
Design, synthesis, and pharmacological evaluation of haloperidol derivatives as novel potent calcium channel blockers with vasodilator activity. PLoS One (2011) 0.81
NO-donating aspirin inhibits angiogenesis by suppressing VEGF expression in HT-29 human colon cancer mouse xenografts. Carcinogenesis (2008) 0.80
Modulation of carcinogen metabolism by nitric oxide-aspirin 2 is associated with suppression of DNA damage and DNA adduct formation. J Biol Chem (2009) 0.80
The differential cell signaling effects of two positional isomers of the anticancer NO-donating aspirin. Int J Oncol (2009) 0.79
A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties. BMC Cancer (2015) 0.79
Quinone-induced activation of Keap1/Nrf2 signaling by aspirin prodrugs masquerading as nitric oxide. Chem Res Toxicol (2012) 0.78
Inhibition of Murine Systemic Leishmaniasis by Acetyl Salicylic Acid via Nitric Oxide Immunomodulation. Iran J Parasitol (2012) 0.76
In vitro evaluation of novel N-acetylalaninate prodrugs that selectively induce apoptosis in prostate cancer cells. BMC Cancer (2014) 0.76
Anti-Inflammatory Drug Design Using a Molecular Hybridization Approach. Pharmaceuticals (Basel) (2011) 0.75
The Antineoplastic Effect of Nitric Oxide-Donating Acetylsalicylic Acid (NO-ASA) in Chronic Lymphocytic Leukemia (CLL) Cells is Highly Dependent on its Positional Isomerism. Ther Adv Hematol (2011) 0.75
Flurbiprofen benzyl nitrate (NBS-242) inhibits the growth of A-431 human epidermoid carcinoma cells and targets β-catenin. Drug Des Devel Ther (2013) 0.75
Structure-activity relationship study of novel anticancer aspirin-based compounds. Mol Med Rep (2011) 0.75
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell (2007) 7.05
Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med (2013) 4.22
The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol (2012) 2.83
Colon cancer stem cells: promise of targeted therapy. Gastroenterology (2010) 2.58
Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev (2008) 2.20
Cancer stem cell niche: the place to be. Cancer Res (2011) 2.14
The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res (2010) 2.12
APRIL modulates B and T cell immunity. J Clin Invest (2002) 2.07
Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell (2011) 1.80
Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum (2010) 1.77
Lipid droplets: a new player in colorectal cancer stem cells unveiled by spectroscopic imaging. Stem Cells (2015) 1.75
Human inflammatory dendritic epidermal cells express a functional histamine H4 receptor. J Invest Dermatol (2008) 1.73
HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci Signal (2010) 1.72
Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc Natl Acad Sci U S A (2006) 1.71
Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity. Cancer Res (2010) 1.71
The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov (2005) 1.67
Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. Clin Cancer Res (2012) 1.60
Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells (2012) 1.55
Activation of the granzyme pathway in children with severe respiratory syncytial virus infection. Pediatr Res (2008) 1.54
Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther (2005) 1.52
The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J Clin Invest (2010) 1.50
The TNF family member APRIL dampens collagen-induced arthritis. Ann Rheum Dis (2012) 1.49
Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res (2010) 1.46
Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. Annu Rev Pharmacol Toxicol (2007) 1.42
APRIL promotes B-1 cell-associated neoplasm. Cancer Cell (2004) 1.34
Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles. BMC Genomics (2005) 1.34
CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34
Molecular identification and targeting of colorectal cancer stem cells. Oncotarget (2010) 1.33
Diazepam-bound GABAA receptor models identify new benzodiazepine binding-site ligands. Nat Chem Biol (2012) 1.31
Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. J Med Chem (2011) 1.30
Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. Nat Neurosci (2010) 1.30
A G(q/11)-coupled mutant histamine H(1) receptor F435A activated solely by synthetic ligands (RASSL). J Biol Chem (2005) 1.29
IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle (2007) 1.29
The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2. Cancer Res (2009) 1.28
HCMV-encoded G-protein-coupled receptors as constitutively active modulators of cellular signaling networks. Trends Pharmacol Sci (2005) 1.27
The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci (2005) 1.26
Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors. Br J Pharmacol (2009) 1.25
Pentameric ligand-gated ion channel ELIC is activated by GABA and modulated by benzodiazepines. Proc Natl Acad Sci U S A (2012) 1.22
The carboxyl terminus of human cytomegalovirus-encoded 7 transmembrane receptor US28 camouflages agonism by mediating constitutive endocytosis. J Biol Chem (2003) 1.20
Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. J Med Chem (2008) 1.20
Keynote review: histamine H3 receptor antagonists reach out for the clinic. Drug Discov Today (2005) 1.19
Granzymes at a glance. J Cell Sci (2006) 1.18
Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J Leukoc Biol (2002) 1.17
Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology (2008) 1.15
A structural insight into the reorientation of transmembrane domains 3 and 5 during family A G protein-coupled receptor activation. Mol Pharmacol (2010) 1.14
Linking agonist binding to histamine H1 receptor activation. Nat Chem Biol (2005) 1.14
Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. Pharmacol Ther (2011) 1.13
Betulinic acid, a natural compound with potent anticancer effects. Anticancer Drugs (2010) 1.11
Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types. Cancer Lett (2006) 1.11
Cancer heterogeneity--a multifaceted view. EMBO Rep (2013) 1.11
Towards small-molecule CXCR3 ligands with clinical potential. ChemMedChem (2008) 1.11
CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U S A (2010) 1.11
APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica (2007) 1.11
Use of acetylcholine binding protein in the search for novel alpha7 nicotinic receptor ligands. In silico docking, pharmacological screening, and X-ray analysis. J Med Chem (2009) 1.11
Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method. J Med Chem (2004) 1.10
Constitutively active Gq/11-coupled receptors enable signaling by co-expressed G(i/o)-coupled receptors. J Biol Chem (2003) 1.10
Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Discov Today (2009) 1.09
Betulinic acid induces cytochrome c release and apoptosis in a Bax/Bak-independent, permeability transition pore dependent fashion. Apoptosis (2009) 1.09
Tumor microvasculature supports proliferation and expansion of glioma-propagating cells. Int J Cancer (2009) 1.08
Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res (2006) 1.06
Molecular and biochemical pharmacology of the histamine H4 receptor. Br J Pharmacol (2009) 1.06
Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame? Cancer Lett (2012) 1.06
The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking. FASEB J (2009) 1.05
Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood (2011) 1.05
Histamine receptors: specific ligands, receptor biochemistry, and signal transduction. Clin Allergy Immunol (2002) 1.05
Antiinflammatory and antinociceptive effects of the selective histamine H4-receptor antagonists JNJ7777120 and VUF6002 in a rat model of carrageenan-induced acute inflammation. Eur J Pharmacol (2007) 1.04
Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists. Bioorg Med Chem Lett (2004) 1.04
Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem (2006) 1.03
CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist. Neuropharmacology (2007) 1.02
CC and CX3C chemokines differentially interact with the N terminus of the human cytomegalovirus-encoded US28 receptor. J Biol Chem (2004) 1.01
N-acetylated Proline-Glycine-Proline induced G-protein dependent chemotaxis of neutrophils is independent of CXCL8 release. Eur J Pharmacol (2011) 1.01
The human cytomegalovirus-encoded chemokine receptor US28 induces caspase-dependent apoptosis. FEBS J (2005) 1.01
Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival. Blood (2011) 1.01
The Epstein-Barr virus-encoded G protein-coupled receptor BILF1 hetero-oligomerizes with human CXCR4, scavenges Gαi proteins, and constitutively impairs CXCR4 functioning. J Biol Chem (2010) 1.01